Yasuo Hamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yasuo Hamamoto has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
Yasuhiro Yamanaka
Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi 320-0834, Japan
6 shared publicationsEtsuko Warita
5 shared publications- Ken Kato
Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
5 shared publications - Tomohiro Nishi
Department of Medical Oncology, Tochigi Cancer Center
5 shared publications - Hiroki Hara
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
4 shared publications Kei Onodera
Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan
4 shared publications
Latest Publications
- Open Access
- 2 May 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 27
Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.
- 2 May 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 27
Open AccessPatient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.
- 16 November 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 10 (1) , 113-117
Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report
Scirrhous gastric cancer tends to disseminate to the peritoneum and retroperitoneum, where it induces fibrosis. Retroperitoneal fibrosis (RPF) frequently causes acute renal failure due to ureteral obstruction and it tends to make many of physicians hesitate to initiate systemic chemotherapy. The present study reported the case of a 68-year-old man who was diagnosed with scirrhous gastric cancer with peritoneal and retroperitoneal dissemination, causing acute renal failure due to RPF. Before initiating systemic chemotherapy, the patient became anuric and introduced hemodialysis (HD). Although the patient's performance status was poor, there were no contraindications, such as active infection or severe complications, for systemic chemotherapy. Weekly 5-FU/l LV (5-FU 600 mg/m2, l-LV 250 mg/m2 on days 1, 8, 15, 22, 29 and 36; 8 weeks/cycle) was selected as the feasible treatment for the patient. After chemotherapy the patient opted to withdraw from HD and suffered from no severe toxicity. This indicates, retrospectively, that earlier systemic chemotherapy administration prior to HD introduction may result in improvement of renal function and avoidance of HD.
- 16 November 2018
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 10 (1) , 113-117
Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report
Scirrhous gastric cancer tends to disseminate to the peritoneum and retroperitoneum, where it induces fibrosis. Retroperitoneal fibrosis (RPF) frequently causes acute renal failure due to ureteral obstruction and it tends to make many of physicians hesitate to initiate systemic chemotherapy. The present study reported the case of a 68-year-old man who was diagnosed with scirrhous gastric cancer with peritoneal and retroperitoneal dissemination, causing acute renal failure due to RPF. Before initiating systemic chemotherapy, the patient became anuric and introduced hemodialysis (HD). Although the patient's performance status was poor, there were no contraindications, such as active infection or severe complications, for systemic chemotherapy. Weekly 5-FU/l LV (5-FU 600 mg/m2, l-LV 250 mg/m2 on days 1, 8, 15, 22, 29 and 36; 8 weeks/cycle) was selected as the feasible treatment for the patient. After chemotherapy the patient opted to withdraw from HD and suffered from no severe toxicity. This indicates, retrospectively, that earlier systemic chemotherapy administration prior to HD introduction may result in improvement of renal function and avoidance of HD.
- 6 September 2018
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (30) , 3187-3198
Management of Challenging Immune-Related Gastrointestinal Adverse Events Associated with Immune Checkpoint Inhibitors
Immune-related gastrointestinal toxicities (irGI) are well-known adverse events (AEs) with immune checkpoint inhibitors. The aim of this review was to present clinical data from 82 cases to provide information to clinicians who face real-world challenges among their patients with irGI AEs. The findings of this review support the use of the current management guidelines. By analyzing the treatment courses and outcomes of all cases identified, our review recommends that recurrent cases be treated carefully regardless of the grade of diarrhea at the onset of events. Earlier gastroenterology consultation and computed tomography/endoscopy diagnosis are essential, especially when an irGI AE recurs or worsens during steroid tapering. We would also suggest earlier decision to add immunosuppressant agents, particularly for recurrent cases.
- 6 September 2018
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (30) , 3187-3198
Management of Challenging Immune-Related Gastrointestinal Adverse Events Associated with Immune Checkpoint Inhibitors
Immune-related gastrointestinal toxicities (irGI) are well-known adverse events (AEs) with immune checkpoint inhibitors. The aim of this review was to present clinical data from 82 cases to provide information to clinicians who face real-world challenges among their patients with irGI AEs. The findings of this review support the use of the current management guidelines. By analyzing the treatment courses and outcomes of all cases identified, our review recommends that recurrent cases be treated carefully regardless of the grade of diarrhea at the onset of events. Earlier gastroenterology consultation and computed tomography/endoscopy diagnosis are essential, especially when an irGI AE recurs or worsens during steroid tapering. We would also suggest earlier decision to add immunosuppressant agents, particularly for recurrent cases.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15768
A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer.
E15768 Background: We previously reported positive relationship between overall survival (OS) and both of postprogression survival (PPS) and post-trial anti-cancer therapies in first-line pancreatic cancer patients. We conducted a meta-analysis to gain a better understanding of the impact of PPS and post-trial anti-cancer therapies on OS and to determine the efficacy of second-line systemic therapy. Methods: We searched randomized trials of second-line systemic therapy for pancreatic cancer patients. We evaluated the relation between OS and either progression-free survival (PFS) or PPS and calculated the pooled effect size by using random effects models. Results: Eleven randomized trials with 23 treatment arms that involved examining 2267 patients were analyzed. Median OS was strongly associated with median PPS and PFS (r = 0.908 and 0.754, respectively), but no correlation between rate of post-trial anti-cancer therapies and OS was detected (r = 0.050). Average OS, PFS and PPS were significantly longer in recent trials than in older trials, (6.08 versus 4.17 months, p < 0.001), (2.65 versus 1.95 months, p < 0.001) and (3.43 versus 2.25 months, p < 0.001), respectively. Overall, experimental therapies compared to control did not significantly improve PFS (HR, 0.83; 95% CI, 0.67-1.03; I2 = 73%) or OS (HR, 0.89; 95% CI, 0.72-1.11; I2 = 69%). When the analysis was restricted to fluoropyrimidine compared to irinotecan or oxaliplatin in combination with fluoropyrimidine, each therapy produced advantage in a term of PFS (HR, 0.65; 95% CI, 0.47-0.88; I2 = 39% for irinotecan, HR, 0.81; 95% CI, 0.67-0.98; I2 = 13% for oxaliplatin) but only irinotecan produced advantage in a term of OS (HR, 0.70; 95% CI, 0.55-0.89; I2 = 0% for irinotecan, HR, 1.04; 95% CI, 0.65-1.65; I2 = 82% for oxaliplatin). Conclusions: Although second-line treatment benefit for OS can be skewed by PPS in patients with gemcitabine-refractory pancreatic cancer, the effects of subsequent therapies are weak in the salvage setting.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15768
A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer.
E15768 Background: We previously reported positive relationship between overall survival (OS) and both of postprogression survival (PPS) and post-trial anti-cancer therapies in first-line pancreatic cancer patients. We conducted a meta-analysis to gain a better understanding of the impact of PPS and post-trial anti-cancer therapies on OS and to determine the efficacy of second-line systemic therapy. Methods: We searched randomized trials of second-line systemic therapy for pancreatic cancer patients. We evaluated the relation between OS and either progression-free survival (PFS) or PPS and calculated the pooled effect size by using random effects models. Results: Eleven randomized trials with 23 treatment arms that involved examining 2267 patients were analyzed. Median OS was strongly associated with median PPS and PFS (r = 0.908 and 0.754, respectively), but no correlation between rate of post-trial anti-cancer therapies and OS was detected (r = 0.050). Average OS, PFS and PPS were significantly longer in recent trials than in older trials, (6.08 versus 4.17 months, p < 0.001), (2.65 versus 1.95 months, p < 0.001) and (3.43 versus 2.25 months, p < 0.001), respectively. Overall, experimental therapies compared to control did not significantly improve PFS (HR, 0.83; 95% CI, 0.67-1.03; I2 = 73%) or OS (HR, 0.89; 95% CI, 0.72-1.11; I2 = 69%). When the analysis was restricted to fluoropyrimidine compared to irinotecan or oxaliplatin in combination with fluoropyrimidine, each therapy produced advantage in a term of PFS (HR, 0.65; 95% CI, 0.47-0.88; I2 = 39% for irinotecan, HR, 0.81; 95% CI, 0.67-0.98; I2 = 13% for oxaliplatin) but only irinotecan produced advantage in a term of OS (HR, 0.70; 95% CI, 0.55-0.89; I2 = 0% for irinotecan, HR, 1.04; 95% CI, 0.65-1.65; I2 = 82% for oxaliplatin). Conclusions: Although second-line treatment benefit for OS can be skewed by PPS in patients with gemcitabine-refractory pancreatic cancer, the effects of subsequent therapies are weak in the salvage setting.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 29
Serum HER2 level during chemotherapy as a biomarker for advanced gastric cancer.
29 Background: Recent studies showed that serum HER2 levels correlated with tissue HER2 status in gastric cancer. The aim of this prospective study (UMIN000006442, 000006445) was to investigate changes in serum HER2 levels and tissue HER2 status during chemotherapy for advanced gastric cancer (AGC). Methods: Chemotherapy (Capecitabine and cisplatin) with and without trastuzumab was administered to patients with HER2-positive and HER2-negative AGC, respectively. Serum HER2 level was measured using chemiluminescense immunoassay (CLIA) at 4 points: at the initial diagnosis, after two cycles of chemotherapy, at the initial evaluation of tumor response, and at the time of progression. If possible, second biopsy was performed at progression to compare tissue HER2 status before and after chemotherapy. Results: Thirty-three patients (14 HER2-positive and 19 HER2-negative) with a median age of 67 years (range 51-80) were recruited. The median baseline serum HER2 level of the HER2-positive group was significantly higher than that of the HER2-negative group (p = 0.038, 12.0 ng/ml (range 6.5-148.0) and 8.2 ng/ml (4.5-27.2), respectively). A Decrease in serum HER2 level was correlated with tumor response in the HER2-positive group while it was not in the HER2-negative group. Tissue samples at the time of progression were obtained in 6 out of 19 HER2-negative cases. Of these, serum HER2 level elevated at progression in 4 cases, and tissue HER2 status has turned to positive at tumor progression in one case. In the HER2-positive group, tissue samples at tumor progression were obtained in 2 cases, and both showed HER2-positive result, same as the initial diagnosis. Conclusions: Serum HER2 could be useful as a response indicator in HER2-positive AGC. Tissue HER2 status may change from negative to positive over time and serum HER2 has a possibility to predict it. Further studies are needed to confirm these findings. Clinical trial information: UMIN000006442,000006445.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 29
Serum HER2 level during chemotherapy as a biomarker for advanced gastric cancer.
29 Background: Recent studies showed that serum HER2 levels correlated with tissue HER2 status in gastric cancer. The aim of this prospective study (UMIN000006442, 000006445) was to investigate changes in serum HER2 levels and tissue HER2 status during chemotherapy for advanced gastric cancer (AGC). Methods: Chemotherapy (Capecitabine and cisplatin) with and without trastuzumab was administered to patients with HER2-positive and HER2-negative AGC, respectively. Serum HER2 level was measured using chemiluminescense immunoassay (CLIA) at 4 points: at the initial diagnosis, after two cycles of chemotherapy, at the initial evaluation of tumor response, and at the time of progression. If possible, second biopsy was performed at progression to compare tissue HER2 status before and after chemotherapy. Results: Thirty-three patients (14 HER2-positive and 19 HER2-negative) with a median age of 67 years (range 51-80) were recruited. The median baseline serum HER2 level of the HER2-positive group was significantly higher than that of the HER2-negative group (p = 0.038, 12.0 ng/ml (range 6.5-148.0) and 8.2 ng/ml (4.5-27.2), respectively). A Decrease in serum HER2 level was correlated with tumor response in the HER2-positive group while it was not in the HER2-negative group. Tissue samples at the time of progression were obtained in 6 out of 19 HER2-negative cases. Of these, serum HER2 level elevated at progression in 4 cases, and tissue HER2 status has turned to positive at tumor progression in one case. In the HER2-positive group, tissue samples at tumor progression were obtained in 2 cases, and both showed HER2-positive result, same as the initial diagnosis. Conclusions: Serum HER2 could be useful as a response indicator in HER2-positive AGC. Tissue HER2 status may change from negative to positive over time and serum HER2 has a possibility to predict it. Further studies are needed to confirm these findings. Clinical trial information: UMIN000006442,000006445.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 4021
Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.
4021 Background: This multicenter phase II trial assessed the safety and efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (IC) and subsequent conversion surgery (CS) for locally advanced unresectable esophageal cancer (LAUEC). Methods: Esophageal cancer patients (pts) with clinical T4 disease and/or unresectable supraclavicular lymph node metastasis were eligible. The treatment starts with 3 cycles of DCF-IC, followed by CS if resectable, or by concurrent radiation plus chemotherapy with 5-fluorouracil and cisplatin (CF-RT) if not resectable. In case of CF-RT, the resectability is re-evaluated at 30 Gy-40Gy, followed by CS if resectable, or by additional CF-RT with total irradiation dose of 60Gy. If resectable after completion of CF-RT, CS is performed. The primary endpoint is 1-year overall survival (OS). We assumed a null hypothesis with 50% and expected 65% of 1-year OS. Results: Characteristics of 48 pts enrolled were as follows: median age, 66 years; PS0/1, 28/20; primary tumor sites, Ut/Mt/Lt, 13/33/2; T3/T4a/T4b, 5/1/42; N0/N1/N2/N3, 4/12/22/10; M0/M1, 39/9. Eleven pts (22.9%) developed febrile neutropenia related to DCF-IC. CS was performed in 20 pts (41.7%), including DCF-CS (n = 18), DCF-CF-RT40Gy-CS (n = 1), and DCF-CF-RT60Gy-CS (n = 1). R0 resection was confirmed in 19 pts (39.6%). Grade ≥ 3 postoperative complications includes 1 recurrent laryngeal nerve palsy, 1 lung infection, 1 wound infection, 1 pulmonary fistula, and 1 dysphagia; but no remarkable postoperative complications were observed in pts who underwent CS. The overall cure rate including R0 resection or the clinical complete response after CF-RT was 47.9%. The estimated 1-year OS was 67.7% and lower limit of 80% confidence interval was 59.5%. The OS for pts who underwent R0 resection was significantly longer than those who did not undergo R0 resection (median survival time: not reached vs. 326 days, p < 0.01). There was 1 treatment-related death in patient who received DCF-CF-RT60Gy. Conclusions: DCF-IC followed by CS showed promising signs of tolerability and efficacy in pts with LAUEC. Clinical trial information: 000011089.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 4021
Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.
4021 Background: This multicenter phase II trial assessed the safety and efficacy of docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (IC) and subsequent conversion surgery (CS) for locally advanced unresectable esophageal cancer (LAUEC). Methods: Esophageal cancer patients (pts) with clinical T4 disease and/or unresectable supraclavicular lymph node metastasis were eligible. The treatment starts with 3 cycles of DCF-IC, followed by CS if resectable, or by concurrent radiation plus chemotherapy with 5-fluorouracil and cisplatin (CF-RT) if not resectable. In case of CF-RT, the resectability is re-evaluated at 30 Gy-40Gy, followed by CS if resectable, or by additional CF-RT with total irradiation dose of 60Gy. If resectable after completion of CF-RT, CS is performed. The primary endpoint is 1-year overall survival (OS). We assumed a null hypothesis with 50% and expected 65% of 1-year OS. Results: Characteristics of 48 pts enrolled were as follows: median age, 66 years; PS0/1, 28/20; primary tumor sites, Ut/Mt/Lt, 13/33/2; T3/T4a/T4b, 5/1/42; N0/N1/N2/N3, 4/12/22/10; M0/M1, 39/9. Eleven pts (22.9%) developed febrile neutropenia related to DCF-IC. CS was performed in 20 pts (41.7%), including DCF-CS (n = 18), DCF-CF-RT40Gy-CS (n = 1), and DCF-CF-RT60Gy-CS (n = 1). R0 resection was confirmed in 19 pts (39.6%). Grade ≥ 3 postoperative complications includes 1 recurrent laryngeal nerve palsy, 1 lung infection, 1 wound infection, 1 pulmonary fistula, and 1 dysphagia; but no remarkable postoperative complications were observed in pts who underwent CS. The overall cure rate including R0 resection or the clinical complete response after CF-RT was 47.9%. The estimated 1-year OS was 67.7% and lower limit of 80% confidence interval was 59.5%. The OS for pts who underwent R0 resection was significantly longer than those who did not undergo R0 resection (median survival time: not reached vs. 326 days, p < 0.01). There was 1 treatment-related death in patient who received DCF-CF-RT60Gy. Conclusions: DCF-IC followed by CS showed promising signs of tolerability and efficacy in pts with LAUEC. Clinical trial information: 000011089.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15687
Meta-analysis of postprogression survival for first-line gemcitabine monotherapy in patients with advanced pancreatic cancer: Positive relationship between subsequent anti-cancer therapy and overall survival.
E15687 Background: With the increasing number of drugs available for pancreatic cancer, the effect of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapy. We examined the relationship between postprogression survival (PPS) and OS in randomized trials of first-line gemcitabine (GEM) monotherapy for advanced unresectable pancreatic cancer. Methods: A literature search identified 56 randomized trials comparing GEM alone with other regimens. We partitioned OS into progression-free survival (PFS) and PPS and evaluated the relation between OS and either PFS or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment. Results: For all 56 trials, PPS was strongly associated with OS (r = 0.858), whereas PFS was moderately associated with OS (r = 0.701). Average OS and PPS were significantly longer in recent trials than in older trials, (7.33 versus 6.15 months, p < 0.001) and (3.68 versus 2.86 months, p < 0.001), respectively. The correlation between OS and PPS in recent trials was much stronger than that in older trials (r = 0.912 versus 0.695). The percentage of patients with post-trial treatment was significantly higher in recent trials than in older trials (52.0% versus 39.7%, p < 0.001). The rate of post-trial anticancer therapy was significantly associated with OS (r = 0.877). Conclusions: We found an increase in median PPS in accordance with an increase in median OS in recent trials compared with older trials and that rate of post-trial anticancer therapy was strongly associated with median OS for patients with pancreatic cancer treated with GEM monotherapy.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15687
Meta-analysis of postprogression survival for first-line gemcitabine monotherapy in patients with advanced pancreatic cancer: Positive relationship between subsequent anti-cancer therapy and overall survival.
E15687 Background: With the increasing number of drugs available for pancreatic cancer, the effect of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapy. We examined the relationship between postprogression survival (PPS) and OS in randomized trials of first-line gemcitabine (GEM) monotherapy for advanced unresectable pancreatic cancer. Methods: A literature search identified 56 randomized trials comparing GEM alone with other regimens. We partitioned OS into progression-free survival (PFS) and PPS and evaluated the relation between OS and either PFS or PPS. We also examined whether any association might be affected by the year of completion of trial enrollment. Results: For all 56 trials, PPS was strongly associated with OS (r = 0.858), whereas PFS was moderately associated with OS (r = 0.701). Average OS and PPS were significantly longer in recent trials than in older trials, (7.33 versus 6.15 months, p < 0.001) and (3.68 versus 2.86 months, p < 0.001), respectively. The correlation between OS and PPS in recent trials was much stronger than that in older trials (r = 0.912 versus 0.695). The percentage of patients with post-trial treatment was significantly higher in recent trials than in older trials (52.0% versus 39.7%, p < 0.001). The rate of post-trial anticancer therapy was significantly associated with OS (r = 0.877). Conclusions: We found an increase in median PPS in accordance with an increase in median OS in recent trials compared with older trials and that rate of post-trial anticancer therapy was strongly associated with median OS for patients with pancreatic cancer treated with GEM monotherapy.
- Open Access
- 6 May 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (6) , 4049-4054
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
Little is known about the clinical impact of salvage panitumumab with irinotecan for metastatic colorectal cancer (mCRC) patients. The present study conducted a single-arm, multicenter phase II trial for mCRC with skin toxicity prevention program. The subjects were mCRC patients with wild-type KRAS, who showed resistance to fluoropyrimidine, oxaliplatin and irinotecan. Panitumumab was administered at a dose of 6 mg/kg every 2 weeks by intravenous infusion over 60 min, and irinotecan was administered at a dose of 100–180 mg/m2 every 2 weeks by intravenous infusion over 90 min, depending on the preceding treatment dose. To prevent skin toxicities, a moisturizer was applied and oral antibiotics (100 mg minocycline twice daily) were initiated for 6 weeks. The primary endpoint was the response rate (RR) determined by independent reviewers. Secondary endpoints were the disease control rate (DCR), progression-free survival (PFS) time, overall survival (OS) time and adverse events. A total of 35 patients were enrolled between October 2010 and March 2012. The median age was 61 years (range, 41–76 years), with 25 male and 10 female patients. The initial irinotecan dose was 150 mg/m2 in 19 patients and 180 mg/m2 in 1 patient. The remaining patients were treated with ≤120 mg/m2. A central review indicated a partial response in 8 patients (22.9%) and stable disease in 6 patients (17.1%), with an RR of 22.9% (95% confidence interval, 12.1–39.0) and a DCR of 40%. The RR of the patients with standard-dose irinotecan (150 or 180 mg/m2) was 30%, although that of low-dose irinotecan (100–120 mg/m2) was 13%. The median PFS time was 2.7 months, and the median OS time was 6.3 months. A grade 3 or above acne-like rash developed in 25.7% of patients. In conclusion, panitumumab and irinotecan as salvage therapy for mCRC KRAS wild-type patients with skin toxicity prevention exhibits limited efficacy. In particular, the effect of low-dose irinotecan with panitumumab appears to be clinically insignificant. Routine use of skin toxicity prevention is currently under evaluation.
- 6 May 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (6) , 4049-4054
Open AccessPhase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
Little is known about the clinical impact of salvage panitumumab with irinotecan for metastatic colorectal cancer (mCRC) patients. The present study conducted a single-arm, multicenter phase II trial for mCRC with skin toxicity prevention program. The subjects were mCRC patients with wild-type KRAS, who showed resistance to fluoropyrimidine, oxaliplatin and irinotecan. Panitumumab was administered at a dose of 6 mg/kg every 2 weeks by intravenous infusion over 60 min, and irinotecan was administered at a dose of 100–180 mg/m2 every 2 weeks by intravenous infusion over 90 min, depending on the preceding treatment dose. To prevent skin toxicities, a moisturizer was applied and oral antibiotics (100 mg minocycline twice daily) were initiated for 6 weeks. The primary endpoint was the response rate (RR) determined by independent reviewers. Secondary endpoints were the disease control rate (DCR), progression-free survival (PFS) time, overall survival (OS) time and adverse events. A total of 35 patients were enrolled between October 2010 and March 2012. The median age was 61 years (range, 41–76 years), with 25 male and 10 female patients. The initial irinotecan dose was 150 mg/m2 in 19 patients and 180 mg/m2 in 1 patient. The remaining patients were treated with ≤120 mg/m2. A central review indicated a partial response in 8 patients (22.9%) and stable disease in 6 patients (17.1%), with an RR of 22.9% (95% confidence interval, 12.1–39.0) and a DCR of 40%. The RR of the patients with standard-dose irinotecan (150 or 180 mg/m2) was 30%, although that of low-dose irinotecan (100–120 mg/m2) was 13%. The median PFS time was 2.7 months, and the median OS time was 6.3 months. A grade 3 or above acne-like rash developed in 25.7% of patients. In conclusion, panitumumab and irinotecan as salvage therapy for mCRC KRAS wild-type patients with skin toxicity prevention exhibits limited efficacy. In particular, the effect of low-dose irinotecan with panitumumab appears to be clinically insignificant. Routine use of skin toxicity prevention is currently under evaluation.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , TPS175
Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.
TPS175 Background: Patients with esophageal cancer refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a human monoclonal IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced esophageal cancer. We conducted phase II, single-arm, multi-center trial in JAPAN (JapicCTI-No.142422).Methods: The target population was esophageal cancer patients aged ≥ 20 years with ECOG performance status of 0 or 1, who had received one or more previous treatments and not pre-selected by PD-L1 status. Nivolumab (3 mg/kg IV Q2W) was administered to patients until observing unacceptable toxicity or disease progression assessed at 6 week intervals. The primary endpoint was the proportion of patients with a confirmed objective response assessed by independent review committee according to RECIST 1.1. Planned sample size was 60 patients (P0 = 5, P1 = 15, α = 0.025 (one-side), 1-β = 0.8). Data cutoff, 17 May 2015.Results:We enrolled 65 patients with esophageal carcinoma: median age 62.0 years (range, 49-80 years); male/female, 54/11; ECOG PS 0/1, 29/36, Histological type was squamous in all pts. The median prior regimens was 3.0 (range, 1-8); 44 patients (67.7%) were treated with prior esophagectomy and 44 patients (67.7%) with prior radiation therapy. There were 64 evaluable patients for efficacy, and 11(17.2%) of 64 patients had objective response (CR/PR, 1/10). 16 (25.0%) of 64 patients had stable disease. The median overall survival was 12.1 months in 64 evaluable patients. The incidence of drug-related Serious AEs was 11 events (9/65 patients): Lung infection(2[3.1%]), Dehydration(2[3.1%]), Interstitial lung disease (2[3.1%]), etc. The patients with grade 3 pneumonitis improved with supportive care. There was no treatment-related death. We will introduce the updated efficacy and safety data of this trial. Conclusions: Nivolumab has meaningful activity and a manageable safety profile in pretreated esophageal cancer. These data support the assessment of nivolumab in randomized, controlled, phase III studies of second-line treatment. Funding: ONO Pharmaceutical CO.,LTD. Bristol-Myers Squibb Clinical trial information: 142422.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , TPS175
Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.
TPS175 Background: Patients with esophageal cancer refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a human monoclonal IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced esophageal cancer. We conducted phase II, single-arm, multi-center trial in JAPAN (JapicCTI-No.142422).Methods: The target population was esophageal cancer patients aged ≥ 20 years with ECOG performance status of 0 or 1, who had received one or more previous treatments and not pre-selected by PD-L1 status. Nivolumab (3 mg/kg IV Q2W) was administered to patients until observing unacceptable toxicity or disease progression assessed at 6 week intervals. The primary endpoint was the proportion of patients with a confirmed objective response assessed by independent review committee according to RECIST 1.1. Planned sample size was 60 patients (P0 = 5, P1 = 15, α = 0.025 (one-side), 1-β = 0.8). Data cutoff, 17 May 2015.Results:We enrolled 65 patients with esophageal carcinoma: median age 62.0 years (range, 49-80 years); male/female, 54/11; ECOG PS 0/1, 29/36, Histological type was squamous in all pts. The median prior regimens was 3.0 (range, 1-8); 44 patients (67.7%) were treated with prior esophagectomy and 44 patients (67.7%) with prior radiation therapy. There were 64 evaluable patients for efficacy, and 11(17.2%) of 64 patients had objective response (CR/PR, 1/10). 16 (25.0%) of 64 patients had stable disease. The median overall survival was 12.1 months in 64 evaluable patients. The incidence of drug-related Serious AEs was 11 events (9/65 patients): Lung infection(2[3.1%]), Dehydration(2[3.1%]), Interstitial lung disease (2[3.1%]), etc. The patients with grade 3 pneumonitis improved with supportive care. There was no treatment-related death. We will introduce the updated efficacy and safety data of this trial. Conclusions: Nivolumab has meaningful activity and a manageable safety profile in pretreated esophageal cancer. These data support the assessment of nivolumab in randomized, controlled, phase III studies of second-line treatment. Funding: ONO Pharmaceutical CO.,LTD. Bristol-Myers Squibb Clinical trial information: 142422.